2. Search Result
Search Result
Results for "

Kidney disease

" in MedChemExpress (MCE) Product Catalog:

292

Inhibitors & Agonists

4

Screening Libraries

6

Biochemical Assay Reagents

16

Peptides

8

Inhibitory Antibodies

44

Natural
Products

28

Isotope-Labeled Compounds

3

Antibodies

1

Click Chemistry

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112879
    Mito-TEMPO
    Maximum Cited Publications
    164 Publications Verification

    		 Calcium Channel PINK1/Parkin Mitochondrial Metabolism Apoptosis Autophagy NOD-like Receptor (NLR) Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
    Mito-TEMPO
  • HY-111372
    Finerenone
    5+ Cited Publications

    BAY 94-8862

    		 Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone
  • HY-N1428C
    Ferric citrate
    5 Publications Verification

    Iron(III) citrate; Zerenex

    		 Reactive Oxygen Species (ROS) Antibiotic Metabolic Disease
    Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .
    Ferric citrate
  • HY-B0202
    Irbesartan
    5+ Cited Publications

    SR-47436; BMS-186295

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Endocrinology
    Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .
    Irbesartan
  • HY-16743
    Ibiglustat
    3 Publications Verification

    Venglustat; SAR402671; GZ402671

    		 Glucosylceramide Synthase (GCS) Metabolic Disease
    Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat
  • HY-B0130
    Perindopril
    5+ Cited Publications

    S-9490

    		 Angiotensin-converting Enzyme (ACE) NF-κB STAT Sirtuin Cardiovascular Disease Neurological Disease Cancer
    Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure .
    Perindopril
  • HY-139290
    RGLS4326
    2 Publications Verification

    RG4326

    		 MicroRNA Metabolic Disease Cancer
    RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM .
    RGLS4326
  • HY-101410
    SDMA
    3 Publications Verification

    Symmetric dimethylarginine; NG,NG'-Dimethyl-L-arginine

    		 Endogenous Metabolite NO Synthase NF-κB Inflammation/Immunology
    SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
    SDMA
  • HY-101277
    Vadadustat
    5+ Cited Publications

    PG-1016548; AKB-6548

    		 HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .
    Vadadustat
  • HY-17609
    Difelikefalin
    1 Publications Verification

    CR-845; FE-202845

    		 Opioid Receptor Neurological Disease Inflammation/Immunology
    Difelikefalin (CR-845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease .
    Difelikefalin
  • HY-18627A
    PFI-2 hydrochloride
    10+ Cited Publications

    (R)-PFI-2 hydrochloride

    		 Histone Methyltransferase Infection Inflammation/Immunology Cancer
    PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC50 value of 2.0  nM and (S)-PFI-2 shows inhibiting activity with IC50  value of 1.0  μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .
    PFI-2 hydrochloride
  • HY-13995A
    Sevelamer (hydrochloride)
    1 Publications Verification

    		 FXR Metabolic Disease Endocrinology
    Sevelamer hydrochloride is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer hydrochloride binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer hydrochloride binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer hydrochloride can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
    Sevelamer (hydrochloride)
  • HY-111372R
    Finerenone (Standard)

    BAY 94-8862 (Standard)

    		 Reference Standards Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone (Standard)
  • HY-171099
    SC-919

    LI-2124

    		 IPK Superfamily Cardiovascular Disease Endocrinology
    SC-919 is an orally active IP6K inhibitor, with an IC50 of < 5.2 nM against IP6K1, < 3.8 nM against IP6K2, and 0.65 nM against IP6K3. By inhibiting the activity of IP6K, SC-919 reduces intracellular IP7 levels, thereby suppressing XPR1-mediated cellular phosphate efflux. SC-919 increases intracellular phosphate and ATP levels while reducing phosphate entry into the bloodstream, thus decreasing plasma phosphate levels. SC-919 can be used in research related to chronic kidney disease and hyperphosphatemia .
    SC-919
  • HY-P99505
    Ziltivekimab

    COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216

    		 Interleukin Related LDLR Inflammation/Immunology Endocrinology
    Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
    Ziltivekimab
  • HY-120274
    Balcinrenone

    AZD9977

    		 Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Balcinrenone (AZD9977) is a potent, selective, and orally active mineralocorticoid receptor (MR) modulator. Balcinrenone is used for heart failure, and chronic kidney disease research .
    Balcinrenone
  • HY-107929
    Calcium polystyrene sulfonate

    Poly(styrenesulfonic acid) calcium salt

    		 Potassium Channel Metabolic Disease
    Calcium polystyrene sulfonate (Poly(styrenesulfonic acid) calcium salt) is an orally active potassium-lowering agent. Calcium polystyrene sulfonate binds potassium in the distal colon in exchange for Ca 2+. Calcium polystyrene sulfonate can be used for the research of hyperkalemia in chronic kidney disease .
    Calcium polystyrene sulfonate
  • HY-B0130A
    Perindopril erbumine
    5+ Cited Publications

    Perindopril (tert-butylamine salt); S-9490 erbumine

    		 Sirtuin NF-κB STAT Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Cancer
    Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure .
    Perindopril erbumine
  • HY-13995B
    Sevelamer carbonate
    1 Publications Verification

    		 FXR Metabolic Disease Endocrinology
    Sevelamer carbonate is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer carbonate binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer carbonate binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer carbonate can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
    Sevelamer carbonate
  • HY-18627
    PFI-2
    10+ Cited Publications

    (R)-PFI-2

    		 Histone Methyltransferase Infection Inflammation/Immunology Cancer
    PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride, a chemical probe, is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC50 value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC50 value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .
    PFI-2
  • HY-163689
    Vicadrostat

    BI 690517

    		 Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Vicadrostat (BI 690517) is an orally active aldosterone synthase (aldosterone synthase) inhibitor, with IC50 values of 19 nM, 16 nM, and 18 μM against human, cynomolgus monkey, and rat aldosterone synthase, respectively. Vicadrostat has an in vivo IC50 of 25 nM for aldosterone synthesis. Vicadrostat exhibits high selectivity for cortisol synthase; it reduces aldosterone production and decreases plasma aldosterone levels. Vicadrostat can be used in the research of chronic kidney disease, heart failure, and hypertension .
    Vicadrostat
  • HY-125944
    MitoTEMPO hydrate
    Maximum Cited Publications
    164 Publications Verification

    		 Mitochondrial Metabolism PINK1/Parkin NOD-like Receptor (NLR) Autophagy Calcium Channel Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
    MitoTEMPO hydrate is a mitochondria-targeted antioxidant . MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
    MitoTEMPO hydrate
  • HY-17623C
    (R)-Tegoprazan

    (R)-CJ-12420; (R)-RQ-00000004

    		 Proton Pump Metabolic Disease
    (R)-Tegoprazan ((R)-CJ-12420; example 3), a benzimidazole derivative, is a potent kidney H +/K +-ATPase inhibitor with an IC50 of 98 nM of canine kidney Na +/K +-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research .
    (R)-Tegoprazan
  • HY-N2057
    Steviol

    		Aquaporin CFTR Chloride Channel Metabolic Disease
    Steviol is the main metabolite of steviol glycosides and an inhibitor of AQP2/CFTR. Steviol slows down the growth of renal cysts by inhibiting the activity of CFTR, reducing the expression of AQP2, and promoting the degradation of AQP2 and CFTR. Steviol can be used in the research of polycystic kidney disease .
    Steviol
  • HY-P11178
    Corisin

    		Apoptosis SARS-CoV Infection Metabolic Disease Inflammation/Immunology
    Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF) .
    Corisin
  • HY-150076
    BLU2864
    2 Publications Verification

    		 PKA Metabolic Disease Cancer
    BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research .
    BLU2864
  • HY-119572
    Sodium zirconium cyclosilicate

    		Biochemical Assay Reagents Inflammation/Immunology
    Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K + in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD) .
    Sodium zirconium cyclosilicate
  • HY-150364A
    Farabursen sodium

    RGLS8429 sodium; RG1015 sodium

    		 MicroRNA Metabolic Disease
    Farabursen sodium (RGLS8429 sodium; RG1015 sodium) is a miR-17 inhibitor. Farabursen sodium inhibits the function of the miR-17 family, relieves the inhibitory effect on miR-17 target genes including PKD1 and PKD2, and increases the level of PC1/2. Farabursen sodium slows the growth of renal cysts, reduces the ratio of kidney weight to body weight, and decreases the cyst index and proliferation index. Farabursen sodium is applicable to research related to autosomal dominant polycystic kidney disease .
    Farabursen sodium
  • HY-150364
    Farabursen

    RGLS8429; RG1015

    		 MicroRNA Metabolic Disease
    Farabursen (RGLS8429; RG1015) is a blood-brain barrier-permeable miR-17 inhibitor. Farabursen derepresses Pkd1 and Pkd2, the target genes of miR-17, increases the levels of PC1 and PC2, and reduces cyst growth. Farabursen decreases renal cyst growth, kidney weight-to-body weight ratio, cyst index, proliferation index, and blood urea nitrogen levels in mouse models. Farabursen is applicable to research related to autosomal dominant polycystic kidney disease .
    Farabursen
  • HY-160004
    PXL770

    		AMPK Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    PXL770 is an orally active, direct allosteric AMP-activated protein kinase (AMPK) activator. PXL770 decreases C26:0 levels, improves mitochondrial respiration, reduces expression of proinflammatory genes and induces expression of compensatory transporters (ABCD2/3) in ALD fibroblasts/lymphocytes. PXL770 normalizes plasma VLCFA levels, significantly reduces elevated VLCFA levels in brain and spinal cord in Abcd1 KO mice. PXL770 improves glycemia, dyslipidemia, and insulin resistance in ob/ob and high-fat diet (HFD)-fed mice. PXL770 can be used for the study of X-linked adrenoleukodystrophy (ALD), autosomal dominant polycystic kidney disease and nonalcoholic steatohepatitis (NASH) .
    PXL770
  • HY-14179
    PPQ-102
    4 Publications Verification

    CFTR Inhibitor

    		 CFTR Others
    PPQ-102 (CFTR Inhibitor) is a reversible CFTR inhibitor that completely inhibits CFTR chloride currents (IC50 ~90 nM). PPQ-102 is not affected by membrane potential-dependent cell allocation or blocking efficiency (uncharged at physiological pH) and effectively prevents cyst enlargement in polycystic kidney disease .
    PPQ-102
  • HY-128442
    Phenyl sulfate

    Phenyl hydrogen sulfate

    		 Endogenous Metabolite Metabolic Disease
    Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker in diabetic kidney disease .
    Phenyl sulfate
  • HY-111547
    M1001

    		HIF/HIF Prolyl-Hydroxylase Cancer
    M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a Kd of 667 nM. M1001 can be used in chronic kidney disease research .
    M1001
  • HY-112961
    Patiromer

    		JAK Interleukin Related STAT Metabolic Disease
    Patiromer is an orally active, selective and non-absorbable intestinal potassium (K +) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca 2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy .
    Patiromer
  • HY-123572
    Bis-T-23

    AG1717

    		 Dynamin HIV Integrase Infection Metabolic Disease Inflammation/Immunology
    Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .
    Bis-T-23
  • HY-P2893A
    Creatinase (Recombinant)

    Creatine amidinohydrolase

    		 Endogenous Metabolite Metabolic Disease
    Creatinase (Recombinant) is a hydrolase responsible for catalyzing the hydrolysis of creatine (HY-W010388) into sarcosine (HY-101037) and urea (HY-Y0271). Creatinase (Recombinant) can be used in conjunction with creatinine deiminase (HY-P2838) and sarcosine oxidase (HY-P2861) in an enzyme cascade reaction to measure creatinine (HY-B0504) levels in blood and urine. Creatinase (Recombinant) is the rate-limiting enzyme in this enzymatic cascade, and the enzymatic quantification of creatinine is an important method for evaluating kidney function .
    Creatinase (Recombinant)
  • HY-P5314
    OK2

    		EGFR STAT Others
    OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .
    OK2
  • HY-149987
    LY3522348

    KHK-IN-3

    		 Ketohexokinase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    KHK-IN-3 (Example 1) is a ketohexokinase (KHK) inhibitor. KHK-IN-3 can be used in the study of kidney disease, nonalcoholic steatohepatitis (NASH), diabetes and heart failure. KHK is a rate-limiting enzyme and fructokinase involved in fructose metabolism. KHK catalyzes the phosphorylation of fructose to fructose-1-phosphate (FIP) at the expense of ATP. The lack of feedback inhibition of fructose metabolism triggers the accumulation of downstream intermediates such as lipogenesis, gluconeogenesis, and oxidative phosphorylation .
    LY3522348
  • HY-132827
    Ocedurenone

    KBP-5074

    		 Mineralocorticoid Receptor Endocrinology
    Ocedurenone is a corticosteroid receptor antagonist. Ocedurenone can be used for the research of kidney disease (WO2018054357, compound I) .
    Ocedurenone
  • HY-139725
    CDK5-IN-1
    1 Publications Verification

    		 CDK Metabolic Disease
    CDK5-IN-1 is a potent CDK5 inhibitor with an IC50 less than 10 nM. CDK5-IN-1 is greater than 100-fold more active against CDK5 than CDK2. CDK5-IN-1 is used for kidney diseases research .
    CDK5-IN-1
  • HY-120441
    CAY10590

    GK115

    		 Phospholipase Prostaglandin Receptor Inflammation/Immunology
    CAY10590 (GK115) is an inhibitor of secreted phospholipase A2 (sPLA2) and can be used for the research of chronic inflammatory kidney diseases .
    CAY10590
  • HY-W416250
    p-Cresol glucuronide

    		Drug Metabolite Cardiovascular Disease
    p-Cresol glucuronide, a metabolite of p-cresol, is a prototype protein-bound uremic toxin. p-Cresol glucuronide is associated with chronic kidney disease (CKD) .
    p-Cresol glucuronide
  • HY-Y0785
    Glyoxal (40% w/w in water)

    		Drug Metabolite Metabolic Disease
    Glyoxal is a cytotoxic α-oxoaldehyde. Glyoxal induces cell damage and promotes protein glycation to form advanced glycation end-products (AGEs). Glyoxal is promising for research of oxidative stress-related diseases (such as atherosclerosis, cataract, Alzheimer's disease), and the formation of calcium oxalate kidney stones .
    Glyoxal (40% w/w in water)
  • HY-145150
    TRPC5-IN-1
    1 Publications Verification

    		 TRP Channel Metabolic Disease
    TRPC5-IN-1 (Compound 6j) is a selective TRPC5 inhibitor with 50.5 % Inhibition for TRPC5 at 3 μM. TRPC5-IN-1 can be used for the research of chronic kidney disease (CKD) .
    TRPC5-IN-1
  • HY-139290A
    RGLS4326 sodium
    2 Publications Verification

    RG4326 sodium

    		 MicroRNA Cancer
    RGLS4326 sodium is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 sodium can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 sodium inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM .
    RGLS4326 sodium
  • HY-101410R
    SDMA (Standard)

    Symmetric dimethylarginine (Standard); NG,NG'-Dimethyl-L-arginine (Standard)

    		 Reference Standards Endogenous Metabolite NO Synthase NF-κB Inflammation/Immunology
    SDMA (Standard) is the analytical standard of SDMA. This product is intended for research and analytical applications. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
    SDMA (Standard)
  • HY-16743B
    Ibiglustat succinate
    3 Publications Verification

    Venglustat succinate; SAR402671 succinate; GZ402671 succinate

    		 Glucosylceramide Synthase (GCS) Neurological Disease
    Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat succinate
  • HY-153092
    Avenciguat

    BI-685509

    		 Guanylate Cyclase Cardiovascular Disease Metabolic Disease
    Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .
    Avenciguat
  • HY-176196
    APOL1-IN-3

    		Apolipoprotein Metabolic Disease
    APOL1-IN-3 (Compound 1) is an APOL1 inhibitor. APOL1-IN-3 can be used in the research of kidney diseases .
    APOL1-IN-3
  • HY-122052
    UK‑396082

    		Thrombin Metabolic Disease
    UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD) .
    UK‑396082

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: